<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565756</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-110-001</org_study_id>
    <nct_id>NCT04565756</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of EXN407</brief_title>
  <official_title>A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exonate Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Exonate Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked,&#xD;
      vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and&#xD;
      tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with&#xD;
      Centre-subfield macular thickness (CMT) between 280-420 µm and Best corrected visual acuity&#xD;
      (BCVA) better than or equal to 69 ETDRS score (approximate Snellen equivalent 20/40 (6/12&#xD;
      letters) in the study eye, which is considered secondary to diabetes mellitus.&#xD;
&#xD;
      This study will provide a basis for further clinical development of EXN407 ophthalmic&#xD;
      solution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">August 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Escalation phase.</measure>
    <time_frame>Assessed starting from Day 1 of treatment to Day 36 in Dose Escalation.</time_frame>
    <description>Measured by frequency and severity of ocular AEs in the study and contralateral eyes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase.</measure>
    <time_frame>Assessed starting from Day 1 of treatment to Day 113 in Dose Expansion phase.</time_frame>
    <description>Measured by frequency and severity of ocular AEs in the study and contralateral eyes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by Tmax.</measure>
    <time_frame>Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.</time_frame>
    <description>Measured by characterizing the PK profile by estimating the time of the maximum plasma drug concentration (Tmax) of EXN407 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by Cmax</measure>
    <time_frame>Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.</time_frame>
    <description>Measured by characterizing the PK profile by estimating the maximum observed drug plasma concentration (Cmax) of EXN407 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by AUC.</measure>
    <time_frame>Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.</time_frame>
    <description>Measured by characterizing the PK profile by estimating the area under the curve (AUC) of EXN407 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by t½.</measure>
    <time_frame>Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.</time_frame>
    <description>Measured by characterizing the PK profile by estimating the apparent elimination half-life (t½) of EXN407 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage (%) of changes in ocular functional measures as assessed using ophthalmoscopy.</measure>
    <time_frame>From Day 1 of Treatment to End of Treatment i.e. assessed upto 36 Days in Dose Escalation and upto 4 months(113 days) in Dose Expansion.</time_frame>
    <description>Measured by the changes from baseline in ophthalmic examination finding through ophthalmoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage (%) of changes in ocular structural measures as assessed using ophthalmoscopy.</measure>
    <time_frame>From Day 1 of Treatment to End of Treatment i.e. assessed upto 36 Days in Dose Escalation and upto 4 months(113 days) in Dose Expansion.</time_frame>
    <description>Measured by the changes from baseline in ophthalmic examination finding through ophthalmoscopy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXN407</intervention_name>
    <description>EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.</description>
    <arm_group_label>Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. BCVA better than or equal to 69 ETDRS score (approximate Snellen equivalent 20/40 or&#xD;
             6/12) in the study eye using the ETDRS visual acuity scale at Screening or BCVA less&#xD;
             than 69 ETDRS score (approximate Snellen equivalent 20/50 or 6/15) but who, in the&#xD;
             Investigator's opinion, is unsuitable for treatment with anti-VEGF by intravitreal&#xD;
             injection or refuses it. Subjects should have no more than a 7-letter difference in&#xD;
             BCVA at Screening and baseline visit.&#xD;
&#xD;
          3. Ocular media is consistent with SD-OCT imaging and cataracts are not expected in the&#xD;
             subject for the duration of the study.&#xD;
&#xD;
          4. The subject has no other retinal disease.&#xD;
&#xD;
          5. Subject or the subject's partner successfully demonstrates their ability to&#xD;
             self-administer/administer eye drops at Screening, with multiple attempts allowed at&#xD;
             the discretion of the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other retinal disease in the study eye, other than centre involved DMO or diabetic&#xD;
             retinopathy.&#xD;
&#xD;
          2. Poor vision (VA 6/60 or worse) in the contralateral eye.&#xD;
&#xD;
          3. Intraocular inflammation (including trace or greater) in the study eye. History of&#xD;
             idiopathic or autoimmune uveitis in either eye.&#xD;
&#xD;
          4. Use of intravitreal anti-VEGF drugs including ranibizumab, bevacizumab, aflibercept in&#xD;
             the study eye within 6 months of the Screening Visit, or in the fellow (non study) eye&#xD;
             within 3 months of the Screening Visit. Use of topical corticosteroids or topical&#xD;
             non-steroidal anti-inflammatory agents in the study eye within 28 days of the&#xD;
             Screening Visit. Use of intravitreal corticosteroids in either eye or systemic&#xD;
             steroids within 12 months of the Screening Visit. Prior use of Iluvien (without time&#xD;
             limitation).&#xD;
&#xD;
          5. Within 180 days prior to the Screening visit, use of medications known to be toxic to&#xD;
             the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine,&#xD;
             chlorpromazine, phenothiazines, tamoxifen, and ethambutol).&#xD;
&#xD;
          6. History of (within 90 days of Screening date) cerebral vascular accident (stroke) or&#xD;
             MI.&#xD;
&#xD;
          7. Significant renal impairment including subjects on chronic renal dialysis and subjects&#xD;
             with a history of nephrectomy or kidney transplant (regardless of renal function).&#xD;
&#xD;
          8. History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions, or severe&#xD;
             allergic responses.&#xD;
&#xD;
          9. Positive pregnancy test (all female subjects of childbearing potential must have a&#xD;
             urine β-human chorionic gonadotropin [hCG] pregnancy test performed at Screening and&#xD;
             within 7 days prior to randomisation) or is known to be pregnant or lactating.&#xD;
&#xD;
         10. Known to have, or history of a positive test result for, hepatitis B or C, HIV,&#xD;
             syphilis, tuberculosis, or COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gillies, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sydney Eye Hospital/Save Sight Institution</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Chang, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sydney Retina Clinic &amp; Day Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjeewa Wickremasinghe,, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Eye Research Australia (CERA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Liew,, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>South West Retina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Chen, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lions Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jolly Gilhotra, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adelaide Eye and Retina Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilson Heriot, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZAVe Clinical Research Management - Retinology Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hemal Mehta, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strathfield Retina Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Davies, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle Eye Hospital Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rohan Merani, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Macquarie University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helene Cass, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marsden Eye Specialists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Taylor</last_name>
    <phone>01223734710</phone>
    <email>Mike.Taylor@exonate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adelaide Eye and Retina Centre</name>
      <address>
        <city>Adelaide</city>
        <state>Australian Capital Territory</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerin Haywood</last_name>
      <phone>+0882123022</phone>
      <email>khaywood@adelaideeye.com.au</email>
    </contact>
    <investigator>
      <last_name>Jolly Gilmore, A/Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray Yung</last_name>
      <phone>+61298122979</phone>
      <email>ray.yung@mq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Rohan Merani, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marsden Eye Specialists</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Forsyth</last_name>
      <phone>+61296357077</phone>
      <email>trish.forsyth@marsdeneye.com</email>
    </contact>
    <investigator>
      <last_name>Helene Cass, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital/Save Sight Institution</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon McKenzie</last_name>
      <phone>+61293827309</phone>
      <email>sharon.mckenzie@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Mark Gillies, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strathfield Retina Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2135</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Shen</last_name>
      <phone>+61297462988</phone>
      <email>jessica.shen@strathfieldretina.com.au</email>
    </contact>
    <investigator>
      <last_name>Hemal Mehta, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Eye Hospital Foundation</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn Emery</last_name>
      <phone>02 4967 6777</phone>
      <email>lyn@huntereyesurgeons.com.au</email>
    </contact>
    <investigator>
      <last_name>Peter Davies, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia (CERA)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuy Chau</last_name>
      <phone>+61399298076</phone>
      <email>thuy.chau@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Sanjeewa Wickremasinghe, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retinology Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3146</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cleopatra Mhlanga</last_name>
      <phone>+61449087807</phone>
      <email>ctm@zave.com.au</email>
    </contact>
    <investigator>
      <last_name>Wilson Heriot, A/Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Corica</last_name>
      <phone>+61893810829</phone>
      <email>tammycorica@lei.org.au</email>
    </contact>
    <investigator>
      <last_name>Fred Chen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Retina Clinic &amp; Day Surgery</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EUGENIA CHU</last_name>
      <phone>+612 9221 1637</phone>
      <email>mailto:echu@sydneyretina.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

